Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 136, Issue 2, Pages 167-180
Publisher
Portland Press Ltd.
Online
2022-01-20
DOI
10.1042/cs20210865
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease
- (2020) Jakob Appel Østergaard et al. JOURNAL OF NEPHROLOGY
- Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis
- (2020) Arpeeta Sharma et al. DIABETES
- MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
- (2019) Rebecca C. Coll et al. Nature Chemical Biology
- The role of inflammasomes in kidney disease
- (2019) Takanori Komada et al. Nature Reviews Nephrology
- A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation
- (2019) CongXiao Zhang et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
- (2018) Paul M Ridker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evidence against a role for NLRP3-driven islet inflammation in db/db mice
- (2018) H.L. Kammoun et al. Molecular Metabolism
- Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension
- (2018) Shalini M Krishnan et al. CARDIOVASCULAR RESEARCH
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes and Kidney Disease: Role of Oxidative Stress
- (2016) Jay C. Jha et al. ANTIOXIDANTS & REDOX SIGNALING
- The NLRP3 inflammasome in kidney disease and autoimmunity
- (2016) Holly L Hutton et al. NEPHROLOGY
- Role of the nucleotide-binding domain-like receptor protein 3 inflammasome in acute kidney injury
- (2015) Yanhui Cao et al. FEBS Journal
- Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
- (2015) Khurrum Shahzad et al. KIDNEY INTERNATIONAL
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
- (2015) Rebecca C Coll et al. NATURE MEDICINE
- Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy
- (2014) Pan Gao et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy
- (2014) J. C. Jha et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis
- (2013) Shun-Min Yang et al. DIABETOLOGIA
- Quercetin and Allopurinol Ameliorate Kidney Injury in STZ-Treated Rats with Regulation of Renal NLRP3 Inflammasome Activation and Lipid Accumulation
- (2012) Chuang Wang et al. PLoS One
- LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile
- (2012) Tarak Srivastava et al. Journal of Cell Communication and Signaling
- The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice
- (2009) A. M. D. Watson et al. DIABETOLOGIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More